ExpressionEdits, a Cambridge, UK-based biotechnology company optimizing protein expression using AI and proprietary intronization technology, raised $13M in Seed funding.
The round was led by Octopus Ventures and redalpine, with participation from BlueYard Capital, Wilbe Capital, Acequia Capital, Amino Collective, and Hawktail.
The company intends to use the funds to accelerate candidate selection for preclinical studies and develop a pipeline of protein-based therapeutics.
Founded in 2021 by Dr. Kärt Tomberg, Professor Allan Bradley, and Dr. Liliana Antunes, ExpressionEdits provides proprietary intronization technology for gene design, which mimickes the natural genetic landscape. Genetic Syntax Engine is a computational gene editing platform that uses advanced AI and deep biological insights to predict and redesign genes to unlock protein expression across therapeutic modalities. The technology aims to improve the effectiveness and precision of gene therapies, allowing for lower doses to achieve therapeutic levels, thus minimizing toxicity, and expanding the genetic toolbox to further support the targeting of specific tissues, and increasing protein expression levels.
The primary focus for the pipeline will be recombinant proteins that have historically faced production and manufacturing challenges based on current technology.
FinSMEs
29/05/2024